MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Eligible patients must have:

• Prostate cancer

• Bone metastases without symptoms

• Lack of response to hormone therapy as evidenced by a rising PSA or clinical progression

Exclusion Criteria:

• Prostate cancer-related bone pain

• Previously received bisphosphonate therapy (e.g. zoledronate)

• Received any investigational treatment within the last 30 days